
Barclays: JP Morgan Cazenove reiterates overweight and 285p target. StanChart: Goldman sachs reiterates neutral. St.James Place: Numis reiterates add and 1050p target. Hargreaves Lansdown: JP Morgan Cazenove reiterates neutral and raises target to 1,100p from 1,050p. UK Mail Group: RBC Capital re
May 20 (Reuters) - Respiratory drugs specialist Vectura Group Plc reported a bigger-than-expected jump in full-year revenue as it raked in higher royalty payments and licensing revenue. The company, which develops and markets drugs for illnesses such as asthma and chronic obstructive pulmon